Red Orbit (Free subscription) | 07/22/2008
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) will announce its second quarter financial results on July 31, and will hold a conference call at 11:00 a.m. ET that day to discuss these results. David P. Holveck, President and Chief Executive Officer, Nancy J.
Red Orbit (Free subscription) | 05/22/2008
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) today announced that Blaine T. Davis has been appointed Vice President, Investor Relations and Corporate Communications. Mr.
Market Wire - Investment Opinion (Free subscription) | 05/05/2008
LONDON (MARKET WIRE) MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for NOVA BIOSOURCE FUELS INC (AMEX: NBF), ENDO PHARMACEUTICALS...
Seeking Alpha (Free subscription) | 04/30/2008
Endo Pharmaceuticals Holdings Inc. (ENDP) Q1 FY08 Earnings Call Complete Story ยป
Market Wire (Free subscription) | 04/30/2008
CHADDS FORD, PA and NEW YORK, NY (MARKET WIRE) Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) and the D. E. Shaw group, a global investment management firm, today announced that they have reached an agreement under which Endo's Board of Directors will nominate William F. Spengler at the 2008 Annual Meeting of Stockholders to serve as a member of the Company's Board of Directors. The D. E. Shaw...
Market Watch (Free subscription) | 04/30/2008
NEW YORK (MarketWatch) -- Endo Pharmaceuticals Inc. said Wednesday that first-quarter earnings rose to $59.5 million, or 44 cents a share, compared to $57.1 million, 43 cents, a year ago. Sales rose to $290.3 million, vs $254.4 million. for Earnings per share for fiscal 2008 are now expected to be between $2.15 and $2.19, up from the prior adjusted diluted earnings per share guidance of $2.03 to $2.07....
Market Wire (Free subscription) | 04/24/2008
CHADDS FORD, PA (MARKET WIRE) Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), a market leader in pain management, will announce its financial results for the first quarter ended March 31, 2008 before the market opens on April 30, 2008, and will hold a conference call at 11:00 a.m. ET that day to discuss these results.
The Earth Times Online Newspaper (Free subscription) | 04/11/2008
CHADDS FORD, PA -- 04/11/08 -- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), a market leader in pain management, announced today that Ivan Gergel, M.D., age 47, has been hired as Executive Vice President, Research & Development. Dr. Gerge..
Market Wire (Free subscription) | 04/11/2008
CHADDS FORD, PA (MARKET WIRE) Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), a market leader in pain management, announced today that Ivan Gergel, M.D., age 47, has been hired as Executive Vice President, Research & Development. Dr. Gergel is filling a position that has been vacant since June 2007.
Market Wire (Free subscription) | 04/10/2008
CHADDS FORD, PA (MARKET WIRE) Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) today announced the pricing of its offering of $345 million aggregate principal amount of 1.75% convertible senior subordinated notes due 2015 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In addition, Endo announced that the initial purchasers...
Market Wire (Free subscription) | 04/09/2008
CHADDS FORD, PA (MARKET WIRE) Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) announced today that its Board of Directors has approved a share repurchase program, authorizing Endo to repurchase in the aggregate up to $750 million of shares of its outstanding common stock. Purchases by Endo under this program may be made from time to time in open market purchases, privately negotiated transactions,...
Philadelphia Inquirer (Free subscription) | 04/08/2008
Endo Pharmaceuticals Holdings Inc., Chadds Ford, said today in a U.S. regulatory filing that it has withdrawn a supplemental new drug application to expand the use of its migraine drug Frova. Endo received a "not approvable" letter in September from the Food and Drug Administration to expand Frova's label to also treat short-term prevention of menstrual migraine.
The Philadelphia Business Journal (Free subscription) | 04/08/2008
Endo Pharmaceuticals Inc. Tuesday withdrew its application to market its Frova pain medicine for the short-term prevention of menstrual migraines. (ENDP)
Red Orbit (Free subscription) | 04/08/2008
Endo Pharmaceuticals, a wholly owned subsidiary of Endo Pharmaceuticals Holdings, has notified the FDA of the withdrawal of the supplemental new drug application for Frova 2.5mg tablets.
Fiercebiotech (Free subscription) | 04/08/2008
Endo Pharmaceuticals says a close reading of a non-approvable letter from the FDA for Frova prompted officials to pull their request to gain approval for the short-term relief of menstrual migraine. Read more...
The last article published by a user on Endo Pharmaceuticals :
sunilnair | 12/26/2007
Financial Markets Research: Endo Pharmaceuticals' Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth Introduction Launched in the US in 1999 as the only topical lidocaine patch, Lidoderm has demonstrated very strong growth year-on-year, with annual growth of 114% in 2003, 73% in 2004, and 36% in 2005. Lidoderm's continued growth in both labeled and off-label...
